Search Results - "Inwards, D. J."

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma by Wilcox, R A, Ristow, K, Habermann, T M, Inwards, D J, Micallef, I N M, Johnston, P B, Colgan, J P, Nowakowski, G S, Ansell, S M, Witzig, T E, Markovic, S N, Porrata, L

“…Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models,…”
Get full text

Bowel perforation in intestinal lymphoma: incidence and clinical features by Vaidya, R., Habermann, T.M., Donohue, J.H., Ristow, K.M., Maurer, M.J., Macon, W.R., Colgan, J.P., Inwards, D.J., Ansell, S.M., Porrata, L.F., Micallef, I.N., Johnston, P.B., Markovic, S.N., Thompson, C.A., Nowakowski, G.S., Witzig, T.E.

“…Perforation is a serious life-threatening complication of lymphomas involving the gastrointestinal (GI) tract. Although some perforations occur as the initial…”
Get full text

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study by Nowakowski, G S, LaPlant, B, Habermann, T M, Rivera, C E, Macon, W R, Inwards, D J, Micallef, I N, Johnston, P B, Porrata, L F, Ansell, S M, Klebig, R R, Reeder, C B, Witzig, T E

“…Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish…”
Get full text

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center by Dispenzieri, A, Seenithamby, K, Lacy, M Q, Kumar, S K, Buadi, F K, Hayman, S R, Dingli, D, Litzow, M R, Gastineau, D A, Inwards, D J, Micallef, I N, Ansell, S M, Johnston, P B, Porrata, L F, Patnaik, M M, Hogan, W J, Gertz, M A A

“…The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of ‘tumor burden’ but…”
Get full text

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma by Inwards, D.J., Fishkin, P.A., LaPlant, B.R., Drake, M.T., Kurtin, P.J., Nikcevich, D.A., Wender, D.B., Lair, B.S., Witzig, T.E.

“…We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for…”
Get full text

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma by JOAO, C, PORRATA, L. F, INWARDS, D. J, ANSELL, S. M, MICALLEF, I. N, JOHNSTON, P. B, GASTINEAU, D. A, MARKOVIC, S. N

“…Autologous stem cell transplantation (ASCT) is an effective treatment strategy for mantle-cell lymphoma (MCL) demonstrating significantly prolonged…”
Get full text

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma by Porrata, L F, Rsitow, K, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Habermann, T M, Witzig, T E, Colgan, J P, Nowakowski, G S, Thompson, C A, Markovic, S N

“…A specific predictor during routine follow-up to ascertain risk for relapse after standard chemotherapy in non-Hodgkin's lymphoma (NHL) has not been…”
Get full text

Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia by ELLIOTT, M. A, TEFFERI, A, LACY, M. Q, MICALLEF, I. N, PORRATA, L. F, LITZOW, M. R, HOGAN, W. J, LETENDRE, L, GASTINEAU, D. A, ANSELL, S. M, DISPENZIERI, A, GERTZ, M. A, HAYMAN, S. R, INWARDS, D. J

“…Prognosis in chronic myelomonocytic leukemia (CMML) is unfavorable and the optimal therapy remains uncertain. Currently, allogeneic stem cell transplantation…”
Get full text

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate by GERTZ, M. A, LACY, M. Q, LITZOW, M. R, DISPENZIERI, A, ANSELL, S. M, ELLIOTT, M. A, GASTINEAU, D. A, INWARDS, D. J, MICALLEF, I. N. M, PORRATA, L. F, TEFFERI, A

“…High-dose chemotherapy and autologous stem cell transplantation are used increasingly to treat patients with light-chain-related amyloidosis (AL)…”
Get full text

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma by PORRATA, L. F, LITZOW, M. R, MICALLEF, I. N. M, MARKOVIC, S. N, INWARDS, D. J, GASTINEAU, D. A, MOORE, S. B, PINEDA, A. A, BUNDY, K. L, PADLEY, D. J, PERSKY, D, ANSELL, S. M

“…Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic…”
Get full text

CD34 cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies by Holtan, S G, Hogan, W J, Elliott, M A, Ansell, S M, Inwards, D J, Porrata, L F, Johnston, P B, Micallef, I N, Lacy, M Q, Gastineau, D A, Litzow, M R

“…The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic…”
Get full text

Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia by KUMAR, S, CHEN, M. G, GASTINEAU, D. A, GERTZ, M. A, INWARDS, D. J, LACY, M. Q, TEFFERI, A, LITZOW, M. R

“…Allogeneic blood and marrow transplantation (BMT) is curative for many patients with high-risk and relapsed acute lymphoblastic leukemia (ALL). However,…”
Get full text

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma by BUADI, F. K, MICALLEF, I. N, TEFFERI, A, INWARDS, D. J, ANSELL, S. M, PORRATA, L. F, DISPENZIERI, A, ELLIOT, M. A, GASTINEAU, D. A, GERTZ, M. A, LACY, M. Q, LITZOW, M. R

“…To evaluate autologous stem cell transplant (ASCT) in older patients with intermediate grade non-Hodgkin's lymphoma (NHL), the Mayo Clinic Rochester BMT…”
Get full text

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation by Costa, L J, Micallef, I N, Inwards, D J, Johnston, P B, Porrata, L F, Ansell, S M

“…We explored the concomitant effect of the International Prognostic Index at the time of relapse (IPI-R) and the time from initial diagnosis to relapse (TTR) on…”
Get full text

Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) by GERTZ, M. A, LACY, M. Q, GASTINEAU, D. A, INWARDS, D. J, CHEN, M. G, TEFFERI, A, KYLE, R. A, LITZOW, M. R

“…This study investigated the response rate and toxicity of blood cell transplantation as treatment for primary amyloidosis (AL). Twenty-three patients had stem…”
Get full text

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma by HOWE, R, MICALLEF, I. N. M, LACY, M. Q, TEFFERI, A, LITZOW, M. R, INWARDS, D. J, ANSELL, S. M, DEWALD, G. W, DISPENZIERI, A, GASTINEAU, D. A, GERTZ, M. A, GEYER, S. M, HANSON, C. A

“…Secondary myelodysplastic syndrome (sMDS) and acute myelogenous leukemia (AML) have been recognized with increasing frequency following autologous stem cell…”
Get full text

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma by PORRATA, Luis F, RISTOW, Kay, THOMPSON, Carrie, MARKOVIC, Svetomir N, COLGAN, Joseph P, HABERMANN, Thomas M, WITZIG, Thomas E, INWARDS, David J, ANSELL, Stephen M, MICALLEF, Ivana N, JOHNSTON, Patrick B, NOWAKOWSKI, Grzegorz S

“…Lymphopenia and tumor-associated macrophages are negative prognostic factors for survival in classical Hodgkin's lymphoma. We, therefore, studied whether the…”
Get full text

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization by Naina, H V, Pruthi, R K, Inwards, D J, Dingli, D, Litzow, M R, Ansell, S M, William, H J, Dispenzieri, A, Buadi, F K, Elliott, M A, Gastineau, D A, Gertz, M A, Hayman, S R, Johnston, P B, Lacy, M Q, Micallef, I N, Porrata, L F, Kumar, S

“…The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying…”
Get full text

Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia by KUMAR, S, CHEN, M. G, GASTINEAU, D. A, GERTZ, M. A, INWARDS, D. J, LACY, M. Q, TEFFERI, A, LITZOW, M. R

“…Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after…”
Get full text

Testicular lymphoma is associated with a high incidence of extranodal recurrence by Fonseca, Rafael, Habermann, Thomas M., Colgan, Joseph P., O'Neill, Brian P., White, William L., Witzig, Thomas E., Egan, Kathleen S., Martenson, James A., Burgart, Lawrence J., Inwards, David J.

“…BACKGROUND Testicular lymphoma is a rare extranodal presentation of non‐Hodgkin lymphoma. The authors report long term follow‐up information regarding a group…”
Get full text